Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUAXS5)

• Drug Name: FP-1039 Drug Info
• Synonyms: FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences

Indication

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1b	[2]

• Cross-matching ID: TTD Drug ID: DMUAXS5

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[5]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[6]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[7]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[9]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[10]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[11]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Antagonist	[3]

References

• [1] ClinicalTrials.gov (NCT01244438) Study of FP-1039 in Subjects With Endometrial Cancers. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Five Prime Therapeutics.
• [3] FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927.
• [4] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [8] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [9] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [11] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)